Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Table 1 Clinicopathologic characteristics of patients with HER2-negative breast cancer included for analysis

Characteristics	Cohort 1: SEER		Cohort 2: FDUSCC		Cohort 3: Publicly available cases		Cohort 4: Publicly available NCT cases
	N = 67,932	%	N = 2,338	%	N = 837	%	N = 483	%
Age, years (IQR)	61 (51–70)		53 (45–60)		55 (45–65)		50 (42–58)
Tumor size
T0–1	42,281	62.2	1,132	48.4	155	38.8	33	6.8
T2	20,253	29.8	1,004	42.9	210	52.6	244	50.5
T3–4	5,398	7.9	202	8.6	34	8.5	206	42.7
Lymph nodes
Negative	47,078	69.3	1,168	50.2	285	47.3	150	31.1
Positive	20,854	30.7	1,161	49.8	317	52.7	333	68.9
Grade
I	17,172	26.2	39	1.7	102	13.2	31	6.8
II	29,359	44.7	1,610	68.9	244	31.6	173	38.1
III and UD	19,129	29.1	689	29.5	426	55.2	250	55.1
Subgroup
ER+/PgR+	50,679	74.6	1,686	72.1	391	46.7	216	44.7
ER+/PgR–	7,075	10.4	177	7.6	130	15.5	72	14.9
ER–/PgR+	561	0.8	34	1.5	36	4.3	17	3.5
ER–/PgR–	9,617	14.2	441	18.9	280	33.5	178	36.9
Median follow-up, months (IQR)	11 (5–17)		37 (25–50)		49 (20–72)		36 (21–49)

FDUSCC Fudan University Shanghai Cancer Center, IQR Interquartile range, NCT Neoadjuvant chemotherapy, SEER Surveillance, Epidemiology and End Results program, UD Undifferentiated

ISSN: 1741-7015